J&J unit and Sunesis pursue enzyme inhibitors
Executive Summary
Sunesis Pharmaceuticals will use its Target Directed Lead Discovery technology to generate small-molecule leads for Johnson & Johnson Pharmaceutical R&D to use against chronic disease targets. J&J will hold exclusive worldwide rights to the resulting products.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice